🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Juvenile Recurrent Respiratory Papillomatosis: Establishment of a French National Cohort (PRR : National Cohort " REPA ")

Recruitingn/aAges any - anyAllImagine Institute
NCT06000527 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Recurrent respiratory papillomatosis (RRP) is a rare disease. However, it is the most common benign laryngeal tumor in children. To date, no epidemiological data are available in France. The aim of this study is to establish the epidemiology of juvenile PPR.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with juvenile PRR (disease onset before age 18) * Followed in the : * The MALO CRMR * One of the MALO network's CCMRs * One of the main correspondent centers Exclusion Criteria: * Patients objecting to the collection of their personal data * Parents of minor patients objecting to the collection of their child's personal data
💊

What it tests

  • Not listed
📍

Where

1 site
hôpital Necker Enfants malades
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy